A Swiss enterprise in Zug — developing drugs, biologics and devices, and uniting that science with a deep intellectual-property base, proprietary artificial intelligence and disciplined financial strategy.
Science personalized. Healthcare modernized.
At its core Aquavit Pharmaceuticals AG is a biotechnology and pharmaceutical company. Around that core it has built the rest of what modern medicine actually requires.
The company develops drugs, biologics and devices and carries them from intellectual property through global market access to asset transactions, backed by financial strategy. Artificial intelligence runs through all of it, and capital gives it force.
In 2025 it integrated Axon Technologies AG — formerly Genève Technologies — bringing a Geneva-born capability in quantitative, data-driven machine intelligence in-house.
The company maintains its own site at aquavit.ai.
What separates medicine from the people and places that need it is rarely scarcity — it is friction.
Real-time, jurisdiction-specific regulatory clearance and reimbursement intelligence — letting a specialty asset move cleanly through the differing rules of every market, at scale.
Orchestrates premium-product distribution and demand across territories — expanding reach and supplier volume without channel conflict.
